GynecologyGynecologyГинекология2079-56962079-5831Consilium Medicum64324010.26442/20795696.2024.4.203083REVIEWОБЗОРReview ArticleHormonal contraception in women with polycystic ovary syndrome: Contraceptive and non-contraceptive effects. A clinical lectureГормональная контрацепция у женщин с синдромом поликистозных яичников: контрацептивные и неконтрацептивные эффекты. Клиническая лекцияhttps://orcid.org/0000-0001-6117-7270PustotinaOlga A.ПустотинаОльга Анатольевна
Russian Federation

D. Sci. (Med.)

д-р мед. наук, проф. каф. акушерства и гинекологии с курсом репродуктивной медицины

pustotina@gmail.comInozemtsev Academy of Medical EducationЧОУ ДПО «Академия медицинского образования им. Ф.И. Иноземцева»271220242643113172012202420122024Copyright ©; 2024, Consilium MedicumCopyright ©; 2024, ООО "Консилиум Медикум"2024Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://gynecology.orscience.ru/2079-5831/article/view/643240

The clinical diversity of polycystic ovary syndrome (PCOS) makes the diagnosis challenging, leaving many women untreated. The article deals in detail with the PCOS diagnosis algorithm and pathogenesis, as well as the adverse impact of PCOS on the reproductive and overall health of women. The necessity of using combined hormonal contraception both to prevent unwanted pregnancy and to reduce the risks associated with PCOS is justified, and the advantages of a chlormadinone-containing combined oral contraceptive in women with hyperandrogenism are given.

Клиническое разнообразие синдрома поликистозных яичников (СПЯ) вызывает значительные трудности в диагностике заболевания, вследствие чего многие женщины остаются без лечения. В статье детально разбираются алгоритм диагностики и патогенез СПЯ, а также негативное влияние СПЯ на репродуктивное и общее здоровье женщин. Обосновывается необходимость применения комбинированной гормональной контрацепции как для предотвращения нежелательной беременности, так и для снижения рисков, ассоциированных с СПЯ, а также приводятся преимущества назначения хлормадинонсодержащего комбинированного орального контрацептива у женщин с гиперандрогенией.

insulin resistancehyperandrogenismpolycystic ovary syndromehormonal contraceptionchlormadinone acetateинсулинорезистентностьгиперандрогениясиндром поликистозных яичниковгормональная контрацепцияхлормадинона ацетатYu O, Christ JP, Schulze-Rath R, et al. Incidence, prevalence, and trends in polycystic ovary syndrome diagnosis: a United States population-based study from 2006 to 2019. Am J Obstet Gynecol. 2023;229(1):39.e1-9e12. DOI:10.1016/j.ajog.2023.04.010Shilpa K, Earlina A, Larysa S. The Clinical Manifestations of Polycystic Ovary Syndrome (PCOS) and The Treatment Options. European Journal of Biology and Medical Science Research. 2023;11:57-91.Tomlinson JA, Pinkney JH, Evans P, et al. Screening for diabetes and cardiometabolic disease in women with polycystic ovary syndrome. The British Journal of Diabetes &Vascular Disease. 2013;13(3):115-23. DOI:10.1177/1474651413495571Teede HJ, Tay CT, Laven JJE, et al. Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023;108(10):2447-49. DOI:10.1210/clinem/dgad463Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41-7. DOI:10.1093/humrep/deh098Christ JP, Cedars MI. Current Guidelines for Diagnosing PCOS. Diagnostics (Basel). 2023;13(6):1113. DOI:10.3390/diagnostics13061113Fischer-Holzhausen S, Röblitz S. Hormonal regulation of ovarian follicle growth in humans: Model-based exploration of cycle variability and parameter sensitivities. J Theor Biol. 2022;547:111150. DOI:10.1016/j.jtbi.2022.111150De Leo V, Musacchio MC, Cappelli V, et al. Genetic, hormonal and metabolic aspects of PCOS: an update. Reprod Biol Endocrinol. 2016;14(1):38. DOI:10.1186/s12958-016-0173-xWawrzkiewicz-Jałowiecka A, Kowalczyk K, Trybek P, et al. In Search of New Therapeutics-Molecular Aspects of the PCOS Pathophysiology: Genetics, Hormones, Metabolism and Beyond. Int J Mol Sci. 2020;21(19):7054. DOI:10.3390/ijms21197054Lie Fong S, Laven JSE, Duhamel A, Dewailly D. Polycystic ovarian morphology and the diagnosis of polycystic ovary syndrome: redefining threshold levels for follicle count and serum anti-Müllerian hormone using cluster analysis. Hum Reprod. 2017;32(8):1723-71. DOI:10.1093/humrep/dex226Silva MSB, Giacobini P. New insights into anti-Müllerian hormone role in the hypothalamic-pituitary-gonadal axis and neuroendocrine development. Cell Mol Life Sci. 2021;78(1):1-6. DOI:10.1007/s00018-020-03576-xNiethammer B, Körner C, Schmidmayr M, et al. Non-reproductive Effects of Anovulation: Bone Metabolism in the Luteal Phase of Premenopausal Women Differs between Ovulatory and Anovulatory Cycles. Geburtshilfe Frauenheilkd. 2015;75(12):1250-7. DOI:10.1055/s-0035-1558298Norman RJ, Morman R, Teede HJ. "Tis but thy name that is my enemy"–the problem with the naming of polycystic ovary syndrome. Fertil Steril. 2023;120(2):249-50. DOI:10.1016/j.fertnstert.2023.03.028Tosi F, Bonora E, Moghetti P. Insulin resistance in a large cohort of women with polycystic ovary syndrome: a comparison between euglycaemic-hyperinsulinaemic clamp and surrogate indexes. Hum Reprod. 2017;32(12):2515-51. DOI:10.1093/humrep/dex308Cassar S, Misso ML, Hopkins WG, et al. Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies. Hum Reprod. 2016;31(11):2619-61. DOI:10.1093/humrep/dew243Lim SS, Davies MJ, Norman RJ, Moran LJ. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2012;18(6):618-37. DOI:10.1093/humupd/dms030Ovalle F, Azziz R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril. 2002;77(6):1095-105. DOI:10.1016/s0015-0282(02)03111-4Unluhizarci K, Karaca Z, Kelestimur F. Role of insulin and insulin resistance in androgen excess disorders. World J Diabetes. 2021;12(5):616-29. DOI:10.4239/wjd.v12.i5.616Joham AE, Norman RJ, Stener-Victorin E, et al. Polycystic ovary syndrome. Lancet Diabetes Endocrinol. 2022;10(9):668-80. DOI:10.1016/S2213-8587(22)00163-2Carlomagno G, Unfer V, Roseff S. The D-chiro-inositol paradox in the ovary. Fertil Steril. 2011;95(8):2515-6. DOI:10.1016/j.fertnstert.2011.05.027Diamanti-Kandarakis E, Papalou O, Kandaraki EA. The Role of Androgen Excess on Insulin Sensitivity in Women. Front Horm Res. 2019;53:50-64. DOI:10.1159/000494902Tuorila K, Ollila MM, Järvelin MR, et al. Hyperandrogenemia in Early Adulthood Is an Independent Risk Factor for Abnormal Glucose Metabolism in Middle Age. J Clin Endocrinol Metab. 2021;106(11):e4621-33. DOI:10.1210/clinem/dgab456Пустотина О.А., Расулова И.А. Влияние миоинозитола и Д-хироинозитола в соотношении 40:1 на гормональные и метаболические показатели у женщин с синдромом поликистозных яичников. Акушерство и гинекология. 2023;9:146-54 [Pustotina OA, Rasulova IA. Vliianie mioinozitola i D-khiroinozitola v sootnoshenii 40:1 na gormonal'nye i metabolicheskie pokazateli u zhenshchin s sindromom polikistoznykh iaichnikov. Akusherstvo i ginekologiia. 2023;9:146-54 (in Russian)].Unfer V, Dinicola S, Russo M. A PCOS Paradox: Does Inositol Therapy Find a Rationale in All the Different Phenotypes? Int J Mol Sci. 2023;24(7). DOI:10.3390/ijms24076213Alviggi C, Conforti A, De Rosa P, et al. The Distribution of Stroma and Antral Follicles Differs between Insulin-Resistance and Hyperandrogenism-Related Polycystic Ovarian Syndrome. Front Endocrinol (Lausanne). 2017;8:117. DOI:10.3389/fendo.2017.00117Genazzani AD, Genazzani AR. Polycystic Ovary Syndrome as Metabolic Disease: New Insights on Insulin Resistance. touchREV Endocrinol. 2023;19(1):71-7. DOI:10.17925/EE.2023.19.1.71Palomba S, Piltonen TT, Giudice LC. Endometrial function in women with polycystic ovary syndrome: a comprehensive review. Hum Reprod Update. 2021;27(3):584-618. DOI:10.1093/humupd/dmaa051Moghetti P, Tosi F, Bonin C, et al. Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome. J Clin Endocrinol Metab. 2013;98(4):E628-37. DOI:10.1210/jc.2012-3908Dai S, Zhang H, Yang F, et al. Effects of IGF-1 on the Three-Dimensional Culture of Ovarian Preantral Follicles and Superovulation Rates in Mice. Biology (Basel). 2022;11(6). DOI:10.3390/biology11060833Young CH, Snow B, DeVore SB, et al. Progesterone stimulates histone citrullination to increase IGFBP1 expression in uterine cells. Reproduction. 2021;162(2):117-27. DOI:10.1530/REP-21-0132Пустотина О.А. Фенотипы синдрома поликистозных яичников. Фарматека. 2023;30(4-5):156-63 [Pustotina OA. Polycystic ovary syndrome phenotypes. Pharmateca. 2023;30(4-5):156-63 (in Russian)]. DOI:10.18565/pharmateca.2023.4-5.156-163WHO/SRH and Johns Hopkins Bloomberg School of Public Health/Center for Communication Programs (CCP), Knowledge SUCCESS. Family Planning: A Global Handbook for Providers (2022 update). Baltimore and Geneva: CCP and WHO, 2022.Национальные медицинские критерии приемлемости методов контрацепции (Адаптированный документ «Медицинские критерии приемлемости использования методов контрацепции ВОЗ, 5-е издание, 2015»). М. 2023 [Natsional'nye meditsinskie kriterii priemlemosti metodov kontratseptsii (Adaptirovannyi dokument «Meditsinskie kriterii priemlemosti ispol'zovaniia metodov kontratseptsii VOZ, 5-e izdanie, 2015»). Moscow. 2023 (in Russian)].Family Planing: A global handbook for providers. Update 4th еdition. 2022. Available at: www.fphandbook.org. Accessed: 15.08.2024.Schrager S, Larson M, Carlson J, et al. Beyond Birth Control: Noncontraceptive Benefits of Hormonal Methods and Their Key Role in the General Medical Care of Women. J Womens Health (Larchmt). 2020;29(7):937-43. DOI:10.1089/jwh.2019.7731Naessén S, Carlström K, Byström B, et al. Effects of an antiandrogenic oral contraceptive on appetite and eating behavior in bulimic women. Psychoneuroendocrinology. 2007;32(5):548-4. DOI:10.1016/j.psyneuen.2007.03.008Honma S, Iwamura S, Iizuka K, et al. Identification and anti-androgenic activity of the metabolites of 17alpha-acetoxy-6-chloropregna-4,6-diene-3,20-dione (chlormadinone acetate) in the rat, rabbit, dog and man. Chem Pharm Bull (Tokyo). 1977;25(8):2019-31. DOI:10.1248/cpb.25.2019Пеcтрикова Т.Ю., Юрасова Е.А., Никоноркина И.Ю. Оценка лечебных эффектов и влияния на сексуальную активность препарата Белара. Гинекология. 2015;17(3):88-92 [Pestrikova TYu, Yurasova EA., Nikonorkina IYu. Evaluation of therapeutic effects and impact on the sexual activity of Belara. Gynecology. 2015;17(3):88-92 (in Russian)].Huber JC, Heskamp ML, Schramm GA. Effect of an oral contraceptive with chlormadinone acetate on depressive mood: analysis of data from four observational studies. Clin Drug Investig. 2008;28(12):783-91. DOI:10.2165/0044011-200828120-00006Contreras CM, Azamar-Arizmendi G, Saavedra M, Hernández-Lozano M. A five-day gradual reduction regimen of chlormadinone reduces premenstrual anxiety and depression: a pilot study. Arch Med Res. 2006;37(7):907-13. DOI:10.1016/j.arcmed.2006.05.001